Total
0
Shares
Respiri (ASX:RSH) teams up with Pharmacy Guild to educate pharmacists on asthma management
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management
  • The Pharmacy Guild represents over 5700 community pharmacies across the country
  • The asthma management will be an online training course with Guild Learning and Development
  • The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing
  • On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each

eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management.

The Pharmacy Guild represents over 5700 community pharmacies across the country.

The agreement is for two years and the education program will be with Guild Learning and Development (GuildEd), which is a learning destination for Australian pharmacists, pharmacy assistants and interns.

The education program is an online training course for asthma patient management, in particular children. This will inform pharmacists to better help patients diagnosed with asthma.

The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing.

Respiri CEO Marjan Mikel says with over 65,000 pharmacists practising in Australia, the company understands the importance of helping educate pharmacists.

"Respiri understands their [pharmacists] importance in helping patients with asthma better manage their condition ensuring a better health outcome and quality of life and the critical need for Respiri to build relationships with these key healthcare professionals to help them better understand how wheezo will help drive these patient outcomes," he said.

"By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor and who already sell a range of asthmatic devices within the pharmacy setting, we see them as a critical determinant in building sales momentum and significant growth within this important channel," he added.

On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each.

RSH by the numbers
More From The Market Herald
Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

" Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

Dental centre operator Pacific Smiles (PSQ) has successfully completed its $15 million placement.
MGC Pharmaceuticals (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) receives boosted ArtemiC order from SPC

MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line.
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" Orthocell (ASX:OCC) granted inclusion on Australian Prostheses List

Regenerative medicine company Orthocell (OCC) has been granted inclusion on the Australian Prostheses List.
Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

" Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

Pharmaceutical company Palla Pharma (PAL) has raised roughly $12.24 million via a placement and institutional entitlement offer.